Rigel to Present at Two Upcoming Investor Conferences

On September 9, 2020 Rigel Pharmaceuticals (Nasdaq: RIGL) reported that Dean Schorno, the company’s chief financial officer, is scheduled to present a company overview at two virtual investor conferences in September (Press release, Rigel, SEP 9, 2020, View Source [SID1234564889]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Presentations:
H.C. Wainwright 22nd Annual Global Investment Conference
Date: Tuesday, September 15, 2020
Time: 1:00pm ET/10:00am PT

Cantor Fitzgerald Virtual Global Healthcare Conference 2020
Date: Wednesday, September 16, 2020
Time: 1:20pm ET/10:20am PT

To access these events live or the archived webcasts, go to the Investors section of the company’s website at www.rigel.com. Please connect to Rigel’s website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

Biomica Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

On September 9, 2020 Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), reported it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Biomica, SEP 9, 2020, https://www.prnewswire.com/news-releases/biomica-announces-participation-at-the-hc-wainwright-22nd-annual-global-investment-conference-on-september-14-16-2020-virtual-conference-301126264.html [SID1234564887]). The conference is being held on September 14-16, 2020 virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Elran Haber, CEO of Biomica, will provide an overview of the Company’s business during a live presentation, scheduled for Wednesday, September 16, 12:30 PM (EDT), and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Evogene Announces Participation at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020 (Virtual Conference)

On September 9, 2020 Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN.TA), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, reported it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Evogene, SEP 9, 2020, https://www.prnewswire.com/news-releases/evogene-announces-participation-at-the-hc-wainwright-22nd-annual-global-investment-conference-on-september-14-16-2020-virtual-conference-301126266.html [SID1234564885]). The conference is being held on September 14-16, 2020 virtually.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Ofer Haviv, President & CEO of Evogene, will provide an overview of the Company’s business during a live presentation, scheduled for Wednesday, September 16, 12:00 PM (EDT), and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.

Bausch Health To Participate At The 18th Annual Morgan Stanley Global Healthcare Conference

On September 9, 2020 Bausch Health Companies Inc. (NYSE/TSX: BHC) reported that Joseph C. Papa, chairman and CEO; Sam Eldessouky, senior vice president and corporate controller; and Arthur J. Shannon, senior vice president and head of Investor Relations and Communications, are scheduled to participate at the virtual 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020 at 1:15 p.m. ET (Press release, Bausch Health, SEP 9, 2020, View Source [SID1234564883]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast and audio archive of the events will be available on the Investor Relations page of the Bausch Health Companies Inc. web site at: View Source

Soligenix Invited to Present at Upcoming Virtual Investor Conferences

On September 9, 2020 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the upcoming virtual investor conferences below (Press release, Soligenix, SEP 9, 2020, View Source [SID1234564880]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Virtual Global Healthcare Conference on Tuesday, September 15 at 1:20 PM Eastern Time. To view the presentation live, please go to View Source The presentation will be archived there for 90 days. For more information about the Cantor Virtual Global Healthcare Conference, please refer to the conference website at View Source

Lake Street Capital Market’s 4th Annual Best Ideas Growth (BIG4) Conference on September 17, with one-on-one and group meetings throughout the day. For more information about the 4th Annual BIG4 Conference, please refer to the conference website at View Source
For further information regarding Soligenix, Inc., please visit the Company’s website at www.soligenix.com.